Rheumatoid Arthritis: Causes, Pathophysiology, and Treatment
Causes and Etiology
Rheumatoid arthritis results from a complex interaction between genetic predisposition (particularly HLA-DRB1 alleles and non-HLA loci), environmental triggers, and immune dysregulation that breaks down immune tolerance. 1, 2
Key etiological factors include:
- Genetic susceptibility: HLA-DRB1 shared epitope alleles confer the strongest genetic risk, though multiple susceptibility loci have been identified through genome-wide association studies 1, 2
- Environmental triggers:
- Hormonal factors: Influence disease manifestation and activity 2
The disease affects approximately 1% of the global population, with genetic factors alone insufficient to explain disease onset—environmental influences are critical co-factors 1.
Pathophysiology
The pathophysiological cascade involves aberrant activation of both innate and adaptive immunity, leading to autoantibody production (rheumatoid factor and anti-citrullinated protein antibodies), chronic synovial inflammation, and progressive joint destruction. 1, 2
Key Molecular Mechanisms:
- Immune cell activation: Dysregulated T cells and B cells drive autoantibody formation and perpetuate inflammation 1
- Cytokine dysregulation: Overproduction of TNF-α, IL-6, and other proinflammatory cytokines sustains the inflammatory cascade 1
- Critical signaling pathways:
- NF-κB pathway (central inflammatory mediator)
- JAK/STAT pathway (cytokine signaling)
- RANK pathway (bone erosion) 2
- Fibroblast-like synoviocytes: Become activated and contribute to pannus formation and cartilage destruction 2
- Oxidative stress: Amplifies tissue damage 2
- Neutrophil extracellular traps (NETs): Contribute to inflammation and joint damage 1
Clinical Manifestations:
- Joint involvement: Typically presents as symmetric polyarthritis, though early and atypical presentations are common 3
- Systemic disease: RA is a systemic autoimmune disorder with multiorgan involvement, not merely a joint disease 3
- Progressive damage: Persistent inflammation leads to cartilage degradation, bone erosion, joint deformities, and functional impairment 1
Treatment Strategies
Early initiation of disease-modifying antirheumatic drugs (DMARDs) following a treat-to-target strategy aiming for remission or low disease activity is the cornerstone of modern RA management. 4, 5
Initial Treatment Algorithm:
First-line therapy: Methotrexate remains the cornerstone conventional synthetic DMARD (csDMARD) for initial treatment 6
Short-term glucocorticoids: Frequently necessary to alleviate symptoms before DMARD onset of action, but should be limited to the lowest effective dose for the shortest possible duration 4
Treatment target: Aim for remission or low disease activity using a treat-to-target approach with regular monitoring 4
Treatment Escalation for Inadequate Response:
When patients fail to respond adequately to conventional synthetic DMARDs, biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) should be initiated. 4, 5
After First TNF Inhibitor Failure:
- Primary failure (never responded): Switch to a different mechanism of action—do not cycle to another TNF inhibitor 4
- Secondary failure (lost response) or intolerance: Either swap to different mechanism or cycle to another TNF inhibitor is acceptable 4
- Preferred approach: Evidence from registry studies and the pragmatic ROC study suggests increased benefits with switching to alternative mechanisms of action (rituximab, abatacept, IL-6 inhibitors, or JAK inhibitors) rather than cycling to another TNF inhibitor 4
- Exception: The GO-AFTER trial and one Argentinian registry showed golimumab can offer clinical benefit after prior TNF inhibitor failure 4
After Non-TNF Biologic Failure:
- Limited evidence exists for cycling within the same mechanism versus switching to different mechanisms 4
- Tailor treatment decisions based on disease characteristics, comorbidities, and potential side effects 4
- SELECT-CHOICE study: Demonstrated upadacitinib superiority over abatacept in patients who failed at least one biological therapy 4
- SELECT-COMPARE post-hoc analysis: Patients switched from adalimumab to upadacitinib had better outcomes than those switched from upadacitinib to adalimab 4
Special Clinical Situations:
- Rheumatoid vasculitis: Rituximab is recommended 4
- Interstitial lung disease: Avoid TNF inhibitors 4
- Age ≥65 years with heavy smoking history or cardiovascular/malignancy risk factors: JAK inhibitors are conditionally recommended only after csDMARD or bDMARD failure, and when bDMARDs are contraindicated or unavailable 4
- Multiple treatment failures: Follow guidelines for difficult-to-treat rheumatoid arthritis 4
Treatment De-escalation in Remission:
For patients in sustained remission (6-12 months), gradually reduce medication doses rather than discontinuing treatment altogether. 4
- Monotherapy: Strongly recommend gradually reducing the biological DMARD dose instead of stopping 4
- Combination therapy: Conditionally recommend reducing biological/targeted synthetic DMARD dose first, followed by conventional synthetic DMARD reduction 4
- Rationale: Tapering significantly reduces flare risk compared to abrupt discontinuation 4
Comorbidity Management:
Cardiovascular disease significantly contributes to disease burden and mortality in RA patients, requiring interdisciplinary management and risk stratification. 3 Internists play a key role in early diagnosis, risk assessment, and long-term care coordination 3.
Emerging Therapeutic Approaches:
Novel strategies under investigation include nanotechnology-based drug delivery systems, biomimetic carriers, liposomal formulations, nanoparticle-based immune modulation, and in situ hydrogels targeting NETs—all aimed at improving efficacy while reducing systemic side effects 1. Precision medicine and multi-omics approaches represent future paradigms for advancing RA prediction, monitoring, and personalized management 2.